When there's a for-profit industry, there's an incentive to sell more potency
Over a quarter-century of global cannabis policy, a new international review has surfaced a distinction that cuts to the heart of how societies manage risk: it is not legalization itself, but the commercial machinery built around it, that drives higher usage and psychiatric harm. Where governments allowed for-profit markets to take root — as in the United States and Canada — the familiar logic of addictive-product economics followed, with stronger products, more users, and more hospital beds filled. Where decriminalization or state-controlled models prevailed, the feared cascade largely did not materialize, suggesting that the question before policymakers is less about whether to permit cannabis and more about who profits from it.
- A landmark review spanning 25 years and multiple continents has found that commercial cannabis markets — not legalization itself — are the engine behind rising psychosis rates and heavier use.
- In the US and Canada, for-profit incentives predictably produced cheaper, higher-potency products, more users, and measurable spikes in mental health hospitalizations.
- Decriminalization across Europe, Africa, and Asia, alongside Uruguay's state-controlled model, showed usage and psychiatric illness rates holding largely steady — puncturing the argument that any loosening of cannabis law opens the floodgates.
- Researchers and criminologists are now urging policymakers to treat commercialization as the critical variable, drawing explicit parallels to the documented harms of the tobacco and alcohol industries.
- The harder question — whether Western democracies can legalize without surrendering control to a multibillion-dollar industry — remains unanswered, with no country yet having managed it.
A major international review of cannabis policy between 2000 and 2025 has arrived at a finding with real consequences for governments weighing reform: the danger lies not in legalization, but in commercialization. Tracking usage rates, product potency, and psychosis diagnoses across dozens of countries, researchers found a consistent pattern — where cannabis entered a for-profit marketplace, harms followed. Where it did not, they largely stayed flat.
In the United States and Canada, commercial markets produced exactly what economic theory would predict. Companies pushed high-potency, lower-cost products because volume and dependency drive revenue. More people used cannabis, the drug grew stronger, and hospitals recorded more patients in psychiatric crisis. The parallel to tobacco and alcohol was, as lead author Tom Freeman of the University of Bath put it, deliberate and unavoidable.
The contrast with other models was striking. Across parts of Europe, Africa, and Asia — where cannabis was decriminalized but not commercialized — usage rates barely shifted and psychiatric illness linked to the drug did not spike. Uruguay, which legalized cannabis in 2013 under strict state control, offered the clearest counterexample: adults may purchase through pharmacies, social clubs, or home cultivation, but the government retains oversight of supply and potency. Legalization without the downstream harms.
In the United Kingdom, where cannabis remains a Class B drug, a recent report commissioned by London's mayor found criminal sanctions falling disproportionately on Black Londoners — stopped and searched five times more often than white residents on drug-related grounds. The new research suggests decriminalization alone would not meaningfully increase use, but commercialization would.
Sir Robin Murray of King's College London acknowledged a growing consensus: commercialization, not legalization itself, is the critical variable. He raised the harder question of whether Western capitalist democracies could legalize without handing the market to a multibillion-dollar industry. So far, none has. Alex Stevens of the University of Sheffield called the review essential reading, noting it directly contradicted the central claim of reform opponents — that legalization inevitably drives usage skyward. The real choice before governments, he argued, is not between prohibition and chaos, but between different models of regulation with measurably different outcomes.
A sweeping review of cannabis policy across the globe over the past quarter-century has landed on a distinction that matters: how a country chooses to sell the drug—or not sell it—shapes whether more people use it and whether more people end up in psychiatric crisis.
Researchers from an international team examined the dramatic policy shifts between 2000 and 2025, tracking what happened to usage rates, product potency, and psychosis diagnoses as countries rewrote their cannabis laws. The pattern that emerged was clear enough to surprise no one who has watched the tobacco industry operate, yet it carries real weight for policymakers now weighing their options.
In places where cannabis entered the commercial marketplace—the United States and Canada chief among them—the data showed a predictable arc. More people began using the drug. The products themselves grew stronger. And hospitals saw a measurable uptick in patients arriving with psychosis and other mental health crises tied to cannabis consumption. The for-profit incentive, it turned out, worked exactly as economic theory would predict: companies pushed cheaper products and high-potency strains because volume and addiction drive revenue.
But in countries that chose a different path, the story diverged sharply. Where cannabis was decriminalized without being commercialized—across parts of Europe, Africa, Asia, and notably in Uruguay—usage rates barely budged. Psychiatric illness linked to the drug did not spike. Uruguay, which became the first nation to fully legalize cannabis in 2013, achieved this by keeping the market under state control. Adults who register can purchase from pharmacies, social clubs, or home cultivation, but the government maintains oversight of supply, potency, and safety. The result: legalization without the harms that followed commercialization elsewhere.
Tom Freeman, a psychology professor at the University of Bath and lead author of the review published in Lancet Psychiatry, framed the findings as encouraging for policymakers considering decriminalization or strict regulation. The distinction matters because it separates the question of whether cannabis itself is dangerous from the question of how it is sold. "When there's a for-profit industry, particularly for an addictive product, there's an incentive to sell cheaper products, and high potency products," Freeman explained. The parallel to alcohol and tobacco was deliberate and unavoidable.
In the United Kingdom, where cannabis remains a Class B drug with penalties up to five years imprisonment, a recent report commissioned by London's mayor argued the criminal sanctions were disproportionate and fell hardest on Black Londoners, who were stopped and searched five times more often than white residents on drug-related suspicion. The research now suggests decriminalization alone would not necessarily open the floodgates to widespread use—but commercialization would.
Sir Robin Murray, a psychiatric researcher at King's College London, acknowledged the field was still young but noted a growing consensus: commercialization, not legalization itself, was the critical variable. North America's experience bore this out. "Legalisation has been followed by rampant commercialisation facilitated by advertising from companies which would like to sell as much cannabis as tobacco at its peak," Murray said. He posed a harder question: whether Western capitalist democracies could legalize without commercializing. "It should be possible, but so far no country has managed this because of the growing power of the multibillion cannabis industry."
Alex Stevens, a criminology professor at the University of Sheffield, called the review essential reading for policymakers. The consistent message from research, he noted, contradicted the central claim of cannabis reform opponents: that legalization inevitably drives usage skyward. "That's not what we see in any of the countries that have done it," Stevens said. The choice before governments was not between prohibition and chaos, but between different models of regulation—each with measurably different outcomes for public health.
Citações Notáveis
When there's a for-profit industry, particularly for an addictive product, there's an incentive to sell cheaper products, and high potency products, because they know that the more they sell, the more money they'll make.— Tom Freeman, University of Bath
Is it possible to legalise without commercialising in western capitalist countries? It should be possible, but so far no country has managed this because of the growing power of the multibillion cannabis industry.— Sir Robin Murray, King's College London
A Conversa do Hearth Outra perspectiva sobre a história
So the study is saying decriminalization doesn't increase use. But commercialization does. What's the actual difference between those two things?
Decriminalization means you won't go to jail for having cannabis, but there's no legal market—it's still underground, still controlled by whoever's selling it illegally. Commercialization means licensed companies can openly sell it for profit, like a liquor store. The incentives flip entirely.
And the companies just naturally push stronger products and lower prices?
That's what the data shows. If your business model depends on volume and repeat customers, you want people using more and getting hooked faster. High potency does both. It's not a conspiracy—it's how capitalism works with addictive products.
Uruguay legalized it but kept it state-controlled. Did that actually work?
By the metrics in this review, yes. Usage didn't spike, psychiatric hospitalizations didn't rise. The state controlled what got sold, how strong it was, where it came from. No advertising, no race to the bottom on price.
But the review also says no Western capitalist country has managed legalization without commercialization. Why?
Because once you legalize, the industry forms and gets powerful. They lobby, they advertise, they push for looser regulations. The tobacco and alcohol industries spent decades doing exactly that. Cannabis is following the same playbook.
So what's the takeaway for a country like the UK thinking about this?
The research suggests you could decriminalize without commercializing—stop arresting people but don't create a for-profit market. That seems to work. But it requires political will to resist the industry pressure that will inevitably come.